Please ensure Javascript is enabled for purposes of website accessibility

Revolutionizing the Way the Body Responds to Injury

Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. In healthy tissue, cells communicate with each other through gap junctions. In injured tissues, disrupted gap junctions can release signals outside of the cells. This signaling can have detrimental effects including inflammation and delayed or incomplete healing. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate healing.

Patents Obtained
$ 0 M+
Research Funding
0 +
Patients Served
in 9 clinical trials
0 %
Retention for 2021-22
Clinical Trials
0 +
Preclinical Studies

aCT1 is designed to impact healing by:

Accelerating the
healing process

Reducing harmful

Offering complete wound healing

Providing safety and comfortable treatment


Granexin® Gel

Learn More


iNexin Eye Drops

Learn More


aCT1 Inhalation Solution

Learn More

Contact us for collaborations or partnership opportunities.